221 related articles for article (PubMed ID: 24485160)
21. Overlapping syndrome with familial partial lipodystrophy, Dunnigan variety and cardiomyopathy due to amino-terminal heterozygous missense lamin A/C mutations.
Subramanyam L; Simha V; Garg A
Clin Genet; 2010 Jul; 78(1):66-73. PubMed ID: 20041886
[TBL] [Abstract][Full Text] [Related]
22. A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.
Imachi H; Murao K; Ohtsuka S; Fujiwara M; Muraoka T; Hosokawa H; Ishida T
Endocrine; 2009 Feb; 35(1):18-21. PubMed ID: 19011997
[TBL] [Abstract][Full Text] [Related]
23. [Familial partial lipodystrophy (Dunnigan syndrome) due to LMNA gene mutation: The first description of its clinical case in Russia].
Sorkina EL; Kalashnikova MF; Melnichenko GA; Tyulpakov AN
Ter Arkh; 2015; 87(3):83-87. PubMed ID: 26027246
[TBL] [Abstract][Full Text] [Related]
24. Lipodystrophy-linked LMNA p.R482W mutation induces clinical early atherosclerosis and in vitro endothelial dysfunction.
Bidault G; Garcia M; Vantyghem MC; Ducluzeau PH; Morichon R; Thiyagarajah K; Moritz S; Capeau J; Vigouroux C; Béréziat V
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2162-71. PubMed ID: 23846499
[TBL] [Abstract][Full Text] [Related]
25. [Biochemical, hormonal and genetic evaluation of the families of two Brazilian patients with type 2 familial partial lipodystrophy].
Caldas D; Silva Júnior WS; Simonetti JP; Costa EV; Farias ML
Arq Bras Endocrinol Metabol; 2013 Nov; 57(8):583-93. PubMed ID: 24343626
[TBL] [Abstract][Full Text] [Related]
26. LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.
Boschmann M; Engeli S; Moro C; Luedtke A; Adams F; Gorzelniak K; Rahn G; Mähler A; Dobberstein K; Krüger A; Schmidt S; Spuler S; Luft FC; Smith SR; Schmidt HH; Jordan J
J Clin Endocrinol Metab; 2010 Apr; 95(4):1634-43. PubMed ID: 20130076
[TBL] [Abstract][Full Text] [Related]
27. LMNA missense mutations causing familial partial lipodystrophy do not lead to an accumulation of prelamin A.
Tu Y; Sánchez-Iglesias S; Araújo-Vilar D; Fong LG; Young SG
Nucleus; 2016 Sep; 7(5):512-521. PubMed ID: 27841971
[TBL] [Abstract][Full Text] [Related]
28. The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.
Wojtanik KM; Edgemon K; Viswanadha S; Lindsey B; Haluzik M; Chen W; Poy G; Reitman M; Londos C
J Lipid Res; 2009 Jun; 50(6):1068-79. PubMed ID: 19201734
[TBL] [Abstract][Full Text] [Related]
29. Familial partial lipodystrophy: a monogenic form of the insulin resistance syndrome.
Hegele RA
Mol Genet Metab; 2000 Dec; 71(4):539-44. PubMed ID: 11136544
[TBL] [Abstract][Full Text] [Related]
30. Homozygous lamin A/C familial lipodystrophy R482Q mutation in autosomal recessive Emery Dreifuss muscular dystrophy.
Wiltshire KM; Hegele RA; Innes AM; Brownell AK
Neuromuscul Disord; 2013 Mar; 23(3):265-8. PubMed ID: 23313286
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic diversity in patients with lipodystrophy associated with LMNA mutations.
Mory PB; Crispim F; Freire MB; Salles JE; Valério CM; Godoy-Matos AF; Dib SA; Moisés RS
Eur J Endocrinol; 2012 Sep; 167(3):423-31. PubMed ID: 22700598
[TBL] [Abstract][Full Text] [Related]
32. A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
Maraldi NM; Capanni C; Mattioli E; Columbaro M; Squarzoni S; Parnaik WK; Wehnert M; Lattanzi G
Acta Biomed; 2007; 78 Suppl 1():207-15. PubMed ID: 17465333
[TBL] [Abstract][Full Text] [Related]
33. Cardiometabolic assessment of lamin A/C gene mutation carriers: a phenotype-genotype correlation.
Kwapich M; Lacroix D; Espiard S; Ninni S; Brigadeau F; Kouakam C; Degroote P; Laurent JM; Tiffreau V; Jannin A; Humbert L; Ben Hamou A; Tard C; Ben Yaou R; Lamblin N; Klug D; Richard P; Vigouroux C; Bonne G; Vantyghem MC;
Diabetes Metab; 2019 Sep; 45(4):382-389. PubMed ID: 30287275
[TBL] [Abstract][Full Text] [Related]
34. Thiazolidinedione response in familial lipodystrophy patients with LMNA mutations: a case series.
Luedtke A; Boschmann M; Colpe C; Engeli S; Adams F; Birkenfeld AL; Haufe S; Rahn G; Luft FC; Schmidt HH; Jordan J
Horm Metab Res; 2012 Apr; 44(4):306-11. PubMed ID: 22274718
[TBL] [Abstract][Full Text] [Related]
35. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C.
Speckman RA; Garg A; Du F; Bennett L; Veile R; Arioglu E; Taylor SI; Lovett M; Bowcock AM
Am J Hum Genet; 2000 Apr; 66(4):1192-8. PubMed ID: 10739751
[TBL] [Abstract][Full Text] [Related]
36. The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress.
Verstraeten VL; Caputo S; van Steensel MA; Duband-Goulet I; Zinn-Justin S; Kamps M; Kuijpers HJ; Ostlund C; Worman HJ; Briedé JJ; Le Dour C; Marcelis CL; van Geel M; Steijlen PM; van den Wijngaard A; Ramaekers FC; Broers JL
J Cell Mol Med; 2009 May; 13(5):959-71. PubMed ID: 19220582
[TBL] [Abstract][Full Text] [Related]
37. The novel loss of function Ile354Val mutation in PPARG causes familial partial lipodystrophy.
Padova G; Prudente S; Vinciguerra F; Sudano D; Baratta R; Bellacchio E; Trischitta V; Vallone A; Sciacca L; Frittitta L
Acta Diabetol; 2020 May; 57(5):589-596. PubMed ID: 31863320
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic diversity and glucocorticoid sensitivity in patients with familial partial lipodystrophy type 2.
Resende ATP; Martins CS; Bueno AC; Moreira AC; Foss-Freitas MC; de Castro M
Clin Endocrinol (Oxf); 2019 Jul; 91(1):94-103. PubMed ID: 30954027
[TBL] [Abstract][Full Text] [Related]
39. A LMNA splicing mutation in two sisters with severe Dunnigan-type familial partial lipodystrophy type 2.
Morel CF; Thomas MA; Cao H; O'Neil CH; Pickering JG; Foulkes WD; Hegele RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2689-95. PubMed ID: 16636128
[TBL] [Abstract][Full Text] [Related]
40. Novel LMNA mutations seen in patients with familial partial lipodystrophy subtype 2 (FPLD2; MIM 151660).
Lanktree M; Cao H; Rabkin SW; Hanna A; Hegele RA
Clin Genet; 2007 Feb; 71(2):183-6. PubMed ID: 17250669
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
